Explanipedia

Taxonomy-free fecal microbiome profiles enable robust prediction of immunotherapy response and toxicity in melanoma Open

Anastasia Lucas, M. Reale, Yuri I. Wolf, Bryant Duong, Yichi Zhang , et al. · 2025

The gut microbiome has been causally linked to the efficacy of immune-checkpoint inhibitor therapy (ICI), prompting numerous clinical trials of microbiome-targeting strategies. Yet, mechanisms by which gut microbiota shape immune responses…

Representing immune profiles with self-supervised set representation learning 4557 Open

Matei Ionita, Jaesik Kim, Yidi Huang, Yonghyun Nam, Michelle L. McKeague , et al. · 2025

Description The immune system is a complex network of cells, orchestrating coordinated responses throughout the human body over a person’s lifetime. Cytometry enables profiling of this network, but current analytical approaches focus on en…

cyMAEv2: learning robust cell representations in mass cytometry without supervision 4582 Open

Matei Ionita, Jonghyun Lee, Yonghyun Nam, Michelle L. McKeague, Victoria Fang , et al. · 2025

Description Batch effects in cytometry lead to inconsistent protein expression measurements and prevent researchers from integrating data from the most well-controlled studies. To address these challenges, we present cyMAEv2, an enhanced s…

Divergent ontogeny of Tissue Resident Memory and Tissue Resident Exhausted CD8<sup>+</sup> T cells underlies distinct functional potential Open

Simone L. Park, Mark M. Painter, Sasikanth Manne, Víctor Alcalde, M. A. McLaughlin , et al. · 2025

Persistent antigen stimulation promotes differentiation of exhausted CD8 + T (T EX ) cells. T EX cells are distinct from circulating memory T (T CIRCM ) cells but share many features with tissue-resident memory (T RM ) cells established fo…

RDTA-13 OUTCOMES AFTER SRS AND IPILIMUMAB/NIVOLUMAB FOR PATIENTS WITH MELANOMA BRAIN METASTASES WITH OR WITHOUT PRIOR CHECKPOINT EXPOSURE Open

Ian Messing, Lauren Linkowski, Matthew D Riina, Xingmei Wang, Harper Hubbeling , et al. · 2025

While ipilimumab/nivolumab has demonstrated promising intracranial activity among patients with melanoma brain metastases (BM), patients with prior immune checkpoint inhibition (ICI) exposure may be at higher risk of worse intracranial dis…

DR5 CAR-T cells target solid tumors and suppress MDSCs with minimal toxicity Open

Huaishan Wang, Shujing Liu, Priyanka Sinha, Fang Liu, Xiaogang Zhang , et al. · 2025

Chimeric antigen receptor (CAR) T cell therapies have poor efficacy in solid tumors due to limited target specificity and an immunosuppressive tumor microenvironment. We investigated death receptor 5 (DR5) as a CAR target based on its high…

Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells Open

Yeye Guo, Huaishan Wang, Shujing Liu, Xiaogang Zhang, Xingyue Zhu , et al. · 2025

Small extracellular vesicles (sEVs) are nanosized vesicles. Death receptor 5 (DR5) mediates extrinsic apoptosis. We engineer DR5 agonistic single-chain variable fragment (scFv) expression on the surface of sEVs derived from natural killer …

Antigen-Specific Profiling Identifies T-bet-Expressing Melanoma-Specific CD8 T Cells Associated with Pathologic Response to Neoadjuvant Anti-PD-1 Open

Guanning Wang, Daniel Yoon, Khushboo Patel, Ajeya Nandi, Tarek Azar , et al. · 2025

Data from Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti–PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival Open

L. Kevin, Tara C. Mitchell, Meaghan Dougher, Cimarron E. Sharon, Gabriella N. Tortorello , et al. · 2024

Purpose:Neoadjuvant anti–PD-1 therapy in melanoma may increase tumor-infiltrating lymphocytes (TIL), and more TIL are associated with better treatment response. A major pathologic response (MPR) in melanoma after neoadjuvant anti–PD-1 ther…

581 Neoadjuvant anti-PD-1 therapy reveals the abundance of tumor-specific intermediate exhausted T cells associated with pathological response Open

Guanning Wang, Daniel Yoon, Khushboo Patel, Tarek Azar, Justin Kim , et al. · 2024

Supplementary Data 1 from Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti–PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival Open

L. Kevin, Tara C. Mitchell, Meaghan Dougher, Cimarron E. Sharon, Gabriella N. Tortorello , et al. · 2024

All supplemental data (Supp Figs S1-S4)

Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti–PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival Open

L. Kevin, Tara C. Mitchell, Meaghan Dougher, Cimarron E. Sharon, Gabriella N. Tortorello , et al. · 2024

Purpose: Neoadjuvant anti–PD-1 therapy in melanoma may increase tumor-infiltrating lymphocytes (TIL), and more TIL are associated with better treatment response. A major pathologic response (MPR) in melanoma after neoadjuvant anti–PD-1 the…

LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity Open

Shin Foong Ngiow, Sasikanth Manne, Yinghui Huang, Tarek Azar, Zeyu Chen , et al. · 2024

Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients Open

Divij Mathew, Melina E. Marmarelis, Caitlin Foley, Joshua Bauml, Darwin Ye , et al. · 2024

Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti–PD-1 (programmed cell death protein 1) im…

Supplementary Figure S3 from FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma Open